Table 1.
Demographic profile of study population and disease-related data for PsO and PsA patients.
| Parameters | All (n = 189) | PsA (n = 154, 81.5%) | PsO (n = 35, 18.5%) | p Value |
|---|---|---|---|---|
| Age (years), mean ± SD | 48.3 ± 14.2 | 49.3 ± 14.0 | 43.5 ± 14.6 | 0.028 |
| Male:female | 112:77 | 90:64 | 22:13 | 0.631 |
| Disease duration (years), mean ± SD | 12.2 ± 10.9 | 12.96 ± 11.14 | 8.83 ± 9.33 | 0.043 |
| Family history, N (%) | 45 (23.8%) | 34 (22%) | 11 (31.4%) | 0.241 |
| Uveitis, N (%) | 6 (3.2%) | 6 (3.9%) | 0 (0%) | 0.342 |
| Body mass index (kg/m2), mean ± SD | 27.56 ± 5.272 | 27.86 ± 5.237 | 26.24 ± 5.312 | 0.136 |
| Nail psoriasis, N (%) | 158 (83.6%) | 126 (82.9%) | 32 (91.4%) | 0.318 |
| cDMARDs, N % | 112 (59%) | 97 (63.0%) | 15 (42.9%) | 0.182 |
| Methotrexate | 71 (37.6%) | 58 (0.4%) | 13 (0.4%) | 0.916 |
| Sulfasalazine | 50 (26.5%) | 49 (31.8%) | 1 (2.9%) | 0.001 |
| Leflunomide | 28 (14.8%) | 27 (17.5%) | 1 (2.9%) | 0.031 |
| Cyclosporine | 6 (3.2%) | 4 (2.6%) | 2 (5.7%) | 0.318 |
| b-DMARDs, N% | 47 (25%) | 43 (27.9%) | 4 (11.4%) | 0.137 |
| TNFi, N % | 24 (12.7%) | 23 (14.9%) | 1 (2.9%) | 0.059 |
| Golimumab | 2 (1.1%) | 2 (1.3%) | 0 (0%) | 0.506 |
| Adalimumab | 16 (8.5%) | 16 (10.4%) | 0 (0%) | 0.050 |
| Etanercept | 6 (3.2%) | 5 (3.2%) | 1 (2.9%) | 0.934 |
| IL17i, N % | 19 (10%) | 18 (11.7%) | 1 (2.9%) | 0.312 |
| Ixekizumab | 2 (1.1%) | 2 (1.3%) | 0 (0%) | 0.506 |
| Secukinumab | 18 (9.5%) | 17 (11.0%) | 1 (2.9%) | 0.149 |
| IL12, 23i, N % | 6 (3.2%) | 4 (2.6%) | 2 (5.7%) | 0.313 |
| Ustekinumab | 6 (3.2%) | 4 (2.6%) | 2 (5.7%) | 0.318 |
| IL23i, N % | 1 (0.5%) | 1 (0.6%) | 0 (0%) | 0.639 |
| Guselkumab | 1 (0.5%) | 0 (0%) | 1 (0.6%) | 0.638 |
| NAPSI (points), mean ± SD | 23.8 ± 23.1 | 21.4 ± 21.4 | 33.9 ± 27.5 | 0.016 |
PsO, psoriasis; PsA, psoriatic arthritis; n, the number of patients; cDMARD, conventional disease-modifying antirheumatic drugs; bDMARDs, biological disease-modifying antirheumatic drugs; TNFi, tumor necrosis factor inhibitor; IL17i, interleukin 17 inhibitor; IL12, 23i, interleukin 12, 23 inhibitor; IL23i, interleukin 23 inhibitor; GUESS, Glasgow Ultrasound Enthesitis Scoring System; NAPSI, nail psoriasis severity index; BUNES, Brown University Nail Enthesis Scale; SD, standard deviation.